Covid-19: India and Pfizer hit impasse over vaccine indemnity demand
Reuters/New Delhi/New York Filed on May 21, 2021 AFP file
Sources say Pfizer has been consistent in its position on indemnity and is not planning to change its approach for a deal with India.
Pfizer and the Indian government are at loggerheads over a demand by the US drugmaker for legal protection from any claims linked to the use of its Covid-19 vaccine in one of the world s biggest markets, two sources told Reuters.
India has not given any manufacturer of a Covid-19 vaccine indemnity against the costs of compensation for any severe side effects, which is a condition Pfizer has obtained in many countries where its shots have already been widely rolled out, including Britain and the United States.